STRIDES PHARMA SCIENCE LIMITED Monday, July 3, 2017
Strides Shasun Limited (Formerly Strides Arcolab Limited) Strides House, Bannerghatta Road,
Bangalore - 560076.
Strides Shasun receives USFDA Approval For Promethazine Hydrochloride Tablets Product to be manufactured at the Bangalore facilityBangalore, July 3, 2017 Strides Shasun Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for Promethazine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg.
According to IMS data, the US market for Promethazine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg is approximately USD 17 Million. The product will be manufactured at the Company's flagship facility at Bangalore and marketed by Strides Pharma Inc. in the US Market.
About Promethazine Hydrochloride TabletsPromethazine Hydrochloride Tablet is used to prevent and treat nausea and vomiting related to certain conditions. It is also used to treat allergy symptoms such as rash, itching, and runny nose.
About Strides Shasun LimitedStrides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.
The Company has global manufacturing foot print with 8 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 2 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com
For further information, please contact:Strides Shasun
Shashank Sinha, Managing Director
+91 80 6784 0335
Vikesh Kumar: +91 80 6784 0827
Kannan. N: +91 98450 54745
Sandeep Baid: +91 80 6784 0791
PR Consultancy
Fortuna PRK Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com
K Priya: +91 9535425418
priya@fortunapr.com
Strides Shasun Limited published this content on 03 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 July 2017 13:05:14 UTC.
Original documenthttp://www.stridesarco.com/pdf/pressrelease/2017/usfda_approval_for_promethazine_hcl_tablets.pdf
Public permalinkhttp://www.publicnow.com/view/DEAEA0F64D02C2605594AFD06003C6EA20071AD5
